{"id":"elexacaftor-ivacaftor-tezacaftor","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Headache"},{"rate":"10–20%","effect":"Nausea"},{"rate":"10–20%","effect":"Diarrhea"},{"rate":"5–15%","effect":"Rash"},{"rate":"5–10%","effect":"Elevated transaminases"},{"rate":"5–10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"f354423a-85c2-41c3-a9db-0f3aee135d8d","title":"TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR) KIT [VERTEX PHARMACEUTICALS INCORPORATED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Elexacaftor and tezacaftor are CFTR correctors that help the mutant CFTR protein fold properly and traffic to the cell surface, while ivacaftor is a CFTR potentiator that increases the channel's open probability once at the membrane. Together, they restore ion and fluid transport in the airways and other organs affected by cystic fibrosis.","oneSentence":"This triple combination corrects defective cystic fibrosis transmembrane conductance regulator (CFTR) protein by enhancing its production, localization, and function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:06.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis in patients aged 6 years and older with at least one F508del-CFTR mutation or other eligible CFTR mutations"}]},"trialDetails":[{"nctId":"NCT05153317","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-17","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT04732910","phase":"","title":"Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT07303621","phase":"","title":"Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-09","conditions":"Cystic Fibrosis (CF)","enrollment":150},{"nctId":"NCT05743946","phase":"PHASE4","title":"Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-04-18","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":32},{"nctId":"NCT07363304","phase":"","title":"Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-12-02","conditions":"Cystic Fibrosis (CF)","enrollment":150},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":"Cystic Fibrosis","enrollment":297},{"nctId":"NCT07102043","phase":"","title":"Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Cystic Fibrosis Related Diabetes","enrollment":30},{"nctId":"NCT07314229","phase":"NA","title":"Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-01-01","conditions":"Cystic Fibrosis (CF), Mucoviscidosis","enrollment":130},{"nctId":"NCT06457451","phase":"NA","title":"Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial","status":"RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-11-25","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT06507956","phase":"","title":"Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-17","conditions":"Cystic Fibrosis","enrollment":270},{"nctId":"NCT06683092","phase":"","title":"Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-05-01","conditions":"Cystic Fibrosis","enrollment":200},{"nctId":"NCT05882357","phase":"PHASE3","title":"Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-06-27","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT06460506","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-11-21","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT06191640","phase":"","title":"Sinus Disease in Young Children With Cystic Fibrosis","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-04-12","conditions":"Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis)","enrollment":80},{"nctId":"NCT04969224","phase":"PHASE3","title":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-12","conditions":"Cystic Fibrosis","enrollment":82},{"nctId":"NCT03525574","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-09","conditions":"Cystic Fibrosis","enrollment":507},{"nctId":"NCT04970225","phase":"NA","title":"Cystic Fibrosis Blood Neutrophils","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Cystic Fibrosis","enrollment":47},{"nctId":"NCT03506061","phase":"PHASE2","title":"Trikafta in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-04","conditions":"Cystic Fibrosis","enrollment":42},{"nctId":"NCT07148739","phase":"PHASE4","title":"Ensuring Access to Optimal Therapy in CF: The ENACT Study","status":"RECRUITING","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2025-06-10","conditions":"Cystic Fibrosis (CF)","enrollment":95},{"nctId":"NCT05752019","phase":"","title":"TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-03-21","conditions":"Cystic Fibrosis, Lung Inflammation, Lung Infection","enrollment":103},{"nctId":"NCT04183790","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-17","conditions":"Cystic Fibrosis","enrollment":64},{"nctId":"NCT06331000","phase":"","title":"Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-04-08","conditions":"Cystic Fibrosis","enrollment":184},{"nctId":"NCT05279040","phase":"","title":"Trikafta Exercise Study in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-10","conditions":"Cystic Fibrosis, Lung Diseases","enrollment":20},{"nctId":"NCT05519020","phase":"","title":"Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2022-07-27","conditions":"Cystic Fibrosis","enrollment":1385},{"nctId":"NCT05818319","phase":"NA","title":"Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-01","conditions":"Cystic Fibrosis (CF), CFTR Gene Mutation","enrollment":30},{"nctId":"NCT04038047","phase":"","title":"A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function","status":"COMPLETED","sponsor":"Nicole Hamblett","startDate":"2019-10-22","conditions":"Cystic Fibrosis","enrollment":490},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT04509050","phase":"","title":"Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children","status":"RECRUITING","sponsor":"Sonya Heltshe","startDate":"2020-11-18","conditions":"Cystic Fibrosis","enrollment":210},{"nctId":"NCT04840862","phase":"PHASE4","title":"Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2022-05-09","conditions":"Drug Drug Interaction","enrollment":6},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT06284577","phase":"NA","title":"Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-01-02","conditions":"Cystic Fibrosis in Children","enrollment":40},{"nctId":"NCT04545515","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-11","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT04602468","phase":"PHASE4","title":"Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal College of Surgeons, Ireland","startDate":"2020-09-03","conditions":"Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children","enrollment":237},{"nctId":"NCT06302270","phase":"","title":"CFTR Modulators in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2024-03-15","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT04058366","phase":"PHASE3","title":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-12-05","conditions":"Cystic Fibrosis","enrollment":251},{"nctId":"NCT06184763","phase":"","title":"Evolution of the 6-minute Walk Test in Patients Treated With ELEXACAFTOR / TEZACAFTOR / IVACAFTOR","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":"Cystic Fibrosis","enrollment":73},{"nctId":"NCT06072365","phase":"","title":"Treatment With Elexacaftor/Tezacaftor/Ivacaftor, in Patients With Cystic Fibrosis and Caloric Intake","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2021-10-21","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT04599465","phase":"PHASE3","title":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-15","conditions":"Cystic Fibrosis","enrollment":69},{"nctId":"NCT04362761","phase":"PHASE3","title":"A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-05-04","conditions":"Cystic Fibrosis","enrollment":172},{"nctId":"NCT05822102","phase":"","title":"Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY","status":"UNKNOWN","sponsor":"National Jewish Health","startDate":"2023-02-09","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT05111145","phase":"PHASE3","title":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-14","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT05937815","phase":"NA","title":"Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-13","conditions":"Cystic Fibrosis","enrollment":253},{"nctId":"NCT04043806","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-09","conditions":"Cystic Fibrosis","enrollment":458},{"nctId":"NCT04537793","phase":"PHASE3","title":"Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-11-19","conditions":"Cystic Fibrosis","enrollment":83},{"nctId":"NCT05699148","phase":"","title":"Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-04-01","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT05675592","phase":"","title":"Trikafta/Kaftrio and Pseudomonas Aeruginosa","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2022-02-22","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT05599230","phase":"","title":"Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.","status":"UNKNOWN","sponsor":"CHC Montlegia","startDate":"2022-09-01","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT05576324","phase":"","title":"Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-12-30","conditions":"Cystic Fibrosis","enrollment":130},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT05200429","phase":"","title":"Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT04923464","phase":"","title":"A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-06-30","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT04684823","phase":"NA","title":"The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-01-15","conditions":"Cystic Fibrosis, Adherence, Medication","enrollment":12},{"nctId":"NCT03691779","phase":"PHASE3","title":"Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-02","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT04105972","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-10-03","conditions":"Cystic Fibrosis","enrollment":176},{"nctId":"NCT04702360","phase":"","title":"ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT04058353","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-28","conditions":"Cystic Fibrosis","enrollment":271},{"nctId":"NCT04056702","phase":"","title":"Impact of Triple Combination CFTR Therapy on Sinus Disease.","status":"UNKNOWN","sponsor":"Jennifer Taylor-Cousar","startDate":"2019-09-05","conditions":"Cystic Fibrosis","enrollment":31},{"nctId":"NCT04058210","phase":"","title":"VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":841,"reaction":"HOSPITALISATION"},{"count":183,"reaction":"LOWER RESPIRATORY TRACT INFECTION"},{"count":139,"reaction":"DEATH"},{"count":94,"reaction":"DRUG INTERACTION"},{"count":91,"reaction":"ANXIETY"},{"count":91,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":90,"reaction":"INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS"},{"count":78,"reaction":"MALAISE"},{"count":74,"reaction":"OFF LABEL USE"},{"count":66,"reaction":"CYSTIC FIBROSIS"}],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kaftrio, Trikafta","ETI, Kaftrio®","Triple Combination CFTR Modulator Therapy","ETI - Elexacaftor/Tezacaftor/Ivacaftor"],"phase":"marketed","status":"active","brandName":"Elexacaftor / Ivacaftor / Tezacaftor","genericName":"Elexacaftor / Ivacaftor / Tezacaftor","companyName":"Nottingham University Hospitals NHS Trust","companyId":"nottingham-university-hospitals-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple combination corrects defective cystic fibrosis transmembrane conductance regulator (CFTR) protein by enhancing its production, localization, and function. Used for Cystic fibrosis in patients aged 6 years and older with at least one F508del-CFTR mutation or other eligible CFTR mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}